The best and worst funds of the first half
By , 1 Jul 16
While gold funds were the out and out winners of the first half of the year, the worst performers were much more of a mixed bag.
Biotechnology
Biotechnology
Biotechnology funds also struggled in the first half, after having a rather good time of things over three years.
AXA Framlington Biotech and Pictet Biotech, in fifth and sixth place respectively fell 18.22% and 18.2%, while Candriam Equities L Biotechnology did marginally better, down 17.85%.
Tags: Gold | Investment Strategy
